AMDS: News


14 December 2005: WHO includes additional antiretroviral products in list of prequalified medicines
The World Health Organization (WHO) today lists seven HIV/AIDS medicines that have received approval or tentative approval by the United States Food and Drug Administration (FDA). The additions follow an agreement signed earlier this year between the two organizations to facilitate the exchange of quality-related information on HIV/AIDS medicines for procurement. WHO's inclusion of the FDA approved medicines adds value to the process by providing a wider selection of products of assured quality into a single comprehensive list.
- More information

1 December 2005: WHO adds more new products to its list of prequalified HIV medicines
Two HIV/AIDS medicines will be added to the World Health Organization's (WHO) list of prequalified products today. The expansion in choice of therapy these medicines will afford is particularly significant today, on World AIDS Day.
- More information

7-8 November 2005: WHO/UNAIDS meeting on the Forecasting of ARV production up till 2010
An increased and secured production of antiretroviral medicines will be required for the efforts aimed at universal access of HIV/AIDS treatment and prevention in low- and middle-income countries, by 2010. UNAIDS and WHO predict that there will be 9,8 million people in developing countries receiving ART by 2010. The necessity to forecast market trends for ARVs has emerged as a major element needed for the expansion of the present ARV production capacity. The AMDS and UNAIDS Secetariat organized an international meeting to discuss forecasting of ARV markets in low- and middle-income countries. Representatives from the pharmaceutical industry observed and participated in the meeting.
- More information

27 September 2005: The Partnership for Supply Chain Management wins the contract with PEPFAR for supply management for HIV/AIDS
Today, the President's Emergency Plan for AIDS Relief, through the U.S. Agency for International Development, announced a contract to strengthen the lifeline of essential drugs and supplies for people living with or affected by HIV/AIDS and other infectious diseases in developing countries. The winning team is called The Partnership for Supply Chain Management (the Partnership) and is a leading consortium of 15 separate institutions from the private sector, non-profit and faith-based community, and is well connected to existing delivery and purchasing systems in the developing world.
- More information

19 September 2005: Tentative approval of generic ARV drugs by US FDA
US the Food and Drug Administration within the U.S. Department of Health and Human Services (HHS/FDA) tentatively approved 4 ZDV formulation produced by Indian generic companies on 19 September 2005. This is an important step in bringing low-cost, high-quality anti-retroviral therapy (ART) to patients under the President's Emergency Plan for AIDS Relief although existing patents and/or exclusivity prevent marketing of these products in the United States. The currently available FDA approved generics are listed in the following link.
- More information

9 September 2005: Quarterly Summary Report of the Global Price Reporting Mechanism (GPRM) for ARVs in Developing Countries
The quarterly report of GPRM reflects data from actual transactions for ARVs in low- and middle-income countries and can be a useful tool in monitoring the prices paid for ARVs by HIV/AIDS treatment programmes in developing countries. The report is based on procurement data by AMDS partners (UNICEF, IDA, MSH, GFATM, and WHO/CPS) that continue to shoulder the effort to keep the GPRM up-to-date.
- Report

29 August 2005: Gilead Reduces Prices for Viread® and Truvada® in the Developing World
Gilead Sciences, Inc. announced a significant price reduction for Viread® (tenofovir disoproxil fumarate) and Truvada® (emtricitabine and tenofovir disoproxil fumarate). Viread and Truvada are now priced at US$17.00 and US$26.25 for a 30-day supply, or $0.57 and $0.87 per day, respectively, for private and public programs treating people with HIV/AIDS in 97 countries. The new prices represent approximately a 31 and 12 per cent reduction in no-profit prices for two drugs.
- Full release ¦ Eligible countries

18 August 2005: Ranbaxy ARV products relisted on WHO prequalification
On the World Health Organization (WHO) has reinstated seven antiretroviral (ARV) medicines manufactured by Ranbaxy Laboratories Ltd which had previously been removed from the WHO list of prequalified medicines. At the same time, three new products produced by Aurobindo Pharma Ltd. have been added to the list.
Full information

August 2005: Latin American countries obtain discounts of up to 55% in HIV/AIDS treatment
Negotiations of August, 2005, between 11 Latin American governments and 26 pharmaceutical companies resulted in 15-55 per cent reduction for ARV drugs used in most common ART regimens in the region.
- New price list ¦ PAHO HIV/AIDS site

March 2005: New list for essential medicines
The WHO Model List of Essential Medicines has been updated every two years since 1977. The latest 14th list was released earlier in 2005. It contains 306 medicines including antiretrovirals.
Essential Drugs List

Technical consultancy needed in procurement and supply management
AMDS is seeking applications from qualified candidates to be included in the roster of consultants to provide technical support to countries.
Full information